14 May 2020 - - US-based specialty pharmaceutical company Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) has inked an exclusive agreement with Clinigen Group plc (AIM: CLIN) to manage the supply and distribution of Gvoke outside of the United States where Gvoke is not currently licensed, the company said.

Xeris received US regulatory approval in 2019 for GVOKE (glucagon) injection, its ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above, and continues to evaluate additional applications to address needs in severe hypoglycemia and related conditions.

Xeris (NASDAQ: XERS) is a specialty pharmaceutical company with a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies.

The company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke.

Its proprietary XeriSol and XeriJect formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous infusion.

With Xeris' technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Xeris is headquartered in Chicago, IL.

Clinigen Group plc is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines.

Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply: clinical trial, unlicensed and licensed medicines. The group has sites in North America, Europe, Africa and Asia Pacific.

Clinigen has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centers of excellence in key long-term growth regions.

The Group works with 22 of the top 25 pharmaceutical companies, interacting with over 15,000 registered users across over 100 countries, and shipping approximately 6.4m units in the year.